Physiological and pathological implications of 5-hydroxymethylcytosine in diseases
Metrics: PDF 2327 views | HTML 2723 views | ?
Jing Liang1, Fan Yang1, Liang Zhao1, Chongwei Bi1 and Benzhi Cai1,2
1 Department of Pharmacology, Harbin Medical University (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin, China
2 Institute of Clinical Pharmacy and Medicine, Academics of Medical Sciences of Heilongjiang Province, Harbin, China
Benzhi Cai, email:
Keywords: 5hmC, TET, methylation, embryogenesis, heart
Received: November 18, 2015 Accepted: April 19, 2016 Published: May 10, 2016
Gene expression is the prerequisite of proteins. Diverse stimuli result in alteration of gene expression profile by base substitution for quite a long time. However, during the past decades, accumulating studies proved that bases modification is involved in this process. CpG islands (CGIs) are DNA fragments enriched in CpG repeats which mostly locate in promoters. They are frequently modified, methylated in most conditions, thereby suggesting a role of methylation in profiling gene expression. DNA methylation occurs in many conditions, such as cancer, embryogenesis, nervous system diseases etc. Recently, 5-hydroxymethylcytosine (5hmC), the product of 5-methylcytosine (5mC) demethylation, is emerging as a novel demethylation marker in many disorders. Consistently, conversion of 5mC to 5hmC has been proved in many studies. Here, we reviewed recent studies concerning demethylation via 5hmC conversion in several conditions and progress of therapeutics-associated with it in clinic. We aimed to unveil its physiological and pathological significance in diseases and to provide insight into its clinical application potential.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.